1032 related articles for article (PubMed ID: 27658867)
1. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
[TBL] [Abstract][Full Text] [Related]
3. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
6. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
7. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
TenoRes Study Group
Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
Bissio E; Barbás MG; Kademián S; Bouzas MB; Salomón H; Cudolá A; Giuliano SF; Falistocco C
Antivir Ther; 2017; 22(7):625-629. PubMed ID: 28234630
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
[TBL] [Abstract][Full Text] [Related]
10. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey.
Ávila-Ríos S; García-Morales C; Valenzuela-Lara M; Chaillon A; Tapia-Trejo D; Pérez-García M; López-Sánchez DM; Maza-Sánchez L; Del Arenal-Sánchez SJ; Paz-Juárez HE; Quiroz-Morales VS; Mehta SR; Smith DM; León-Juárez EA; Magis-Rodríguez C; Reyes-Terán G;
J Antimicrob Chemother; 2019 Apr; 74(4):1044-1055. PubMed ID: 30597094
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15.
Bissio E; Barbás MG; Bouzas MB; Cudolá A; Salomón H; Espínola L; Fernández Giuliano S; Kademián S; Mammana L; Ornani ML; Ravasi G; Vila M; Zapiola I; Falistocco C
J Antimicrob Chemother; 2017 Feb; 72(2):504-510. PubMed ID: 27789684
[TBL] [Abstract][Full Text] [Related]
14. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
15. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
[TBL] [Abstract][Full Text] [Related]
16. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
18. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
[TBL] [Abstract][Full Text] [Related]
20. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
